Sklerostin i ego ingibitory - novaya kontseptsiya v lechenii zabolevaniy kostey: izvestnoe proshloe, mnogoobeshchayushchee budushchee


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In accordance with the modern concept of the treatment of osteoporosis (OP), antiresorptive agents are first-line drugs for reducing the risk of bone fractures in patients with OP, and anabolic drugs are usually recommended only in patients with severe OP. in the case of bone ,ass loss, the microstructure of bone (microarchitectonics) cannot be restored only by influencing the function of osteoclasts. Thus, the future treatment paradigm for OP will be aimed at reversing OP due to maximize the bone mass and microarchitectural conservation at an early stage, and the results will be maintained using antiresorptive therapy at the second stage.

Full Text

Restricted Access

About the authors

I. Yu Golovach

References

  1. Дыдыкина И.С., Веткова Е.С. Cклеростин и его роль в регуляции метаболизма костной ткани. Науч.-практич. ревматол. 2013;3(51): 296-301.
  2. Agholme F., Macias B., Hamang M., et al. Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing. Orthop. Res. 2014; 3(32):471-76.
  3. Becker C.B. Sclerostin inhibition for osteoporosis - a new approach. N. Engl. J. Med. 2014;5(370):476-77.
  4. Benson Ch., Robins D., Recker R., et al. Effect of blosozumab on bone mineral density: results of a phase 2 study of postmenopausal women with low bone mineral density. Bone Abstracts. 2013;1:OC5.3.
  5. Boonen S., Marin F., Obermayer-Pietsch B., et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. Clin. Endocrinol. Metab. 2008;3(93):852-60.
  6. Byrne F.R., Morony S., Warmington K., et al. CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut. 2005;54:78-86.
  7. Compston J., Cooper A., Cooper C., et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009;62:105-8.
  8. Drake M., Farr J.N. Inhibitors of sclerostin; emerging concepts. Curr. Opin. Rheumatol. 2014;26(40):45-52.
  9. Eddleston A., Marenzana M., Moore A.R., et al. Short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J. Bone Miner. Res. 2009;24:1662-71.
  10. Garnero Р. Sclerostin - a specific biochemical marker of osteocyte function. Lyon, 2011. 20 p.
  11. Hamann C, Rauner M., Hohna Y., et al. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J. Bone Miner. Res. 2013;3(28):627-38.
  12. Ke H.Z., Richards W.G., Li X., et al. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012;5(33):747-83.
  13. Kim J.H., Liu X., Wang J., et al. Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther. Adv. Musculoskelet. Dis. 2013;1(5):13-31.
  14. Kirmani S., Moedder U., Hoey K., et al. Gender differences in circulating sclerostin levels are established during puberty and correlate with ortical porosity. J. Bone Miner. Res. 2010;1(25):S54.
  15. Korkosz M., Gasowski J., Leszczynski P., et al. High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage. BMC Musculoskeletal Disorders. 2013; 14:99-104.
  16. Lewieski E.M. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther. Adv. Musculoskelet. Dis. 2014;2(6):48-57.
  17. Li C.Y., Tan H.L., Barrero M., et al. Sclerostin antibody treatment enhances fracture healing and increases bone mass and strength in non-fractured bones in an adult rat closed femoral fracture model. J. Bone Miner. Res. 2010;1(25):S129.
  18. Li X., Warmington K.S., Niu Q.T., et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J. Bone Miner. Res. 2010;12(25):2647-56.
  19. Lippuner K. The future of osteoporosis treatment - a research update. Swiss Med. Wkly. 2012;19(142):13624.
  20. McClung M., Grauer A., Boonen S., et al. Inhibition of sclerostin with AMG785 in postmenopausal women with low bone mineral density: phase 2 trial results. J. Bone Miner. Res. 2013;1(27):S8.
  21. McClung M.R., Grauer A., Boonen S., et al. Romosozumab in Postmenopausal Women with Low Bone Mineral Density. N. Engl. J. Med. 2014;5(370):412-20.
  22. McColm J., Hu L., Womack T., et al. Single- and multiple-dose randomized studies of blosozum-ab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J. Bone Miner. Res. 2014;4(29):935-43.
  23. McColm J., Womack T., Hu L., et al. Blosozumab, a humanized monoclonal antibody against sclerostin, demonstrated anabolic effects on bone in postmenopausal women. J. Bone Miner. Res. 2012;1(27):S9.
  24. Mirza F.S., Padhi I.D., Raisz L.G., et al. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J. Clin. Endocrinol. Metab. 2010;4(95):1991-97.
  25. Modder U.I.L., Clowes J.A., Hoey K., et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J. Bone Miner. Res. 2011;1(26);27-34.
  26. Moester M.J., Papapoulos S.E., Lowik C.W., et al. Sclerostin: current knowledge and future perspectives. Calcif. Tissue Int. 2010;2(87):99-107.
  27. Ominsky M., Samadfan R., Jolette J., et al. Sclerostin monoclonal antibody stimulates bone formation and improves the strength and density of the fracture callus and lumbar spine in a primate fibular osteotomy model. J. Bone Miner. Res. 2009;1(25):S.89-S90.
  28. Ominsky M.S., Li C., Li X., et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J. Bone Miner. Res. 2011;5(26):1012-21.
  29. Ominsky M.S., Niu Q.-T., Li Ch., et al. Tissue-Level Mechanisms Responsible for the Increase in Bone Formation and Bone Volume by Sclerostin Antibody. J.Bone Miner. Res. 2014;6(29):1424-30.
  30. Ominsky M.S., Vlasseros F., Jolette J., et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J. Bone Miner. Res. 2010;5(25):948-59.
  31. Padhi D., Jang G., Stouch B., et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 2011;1(26):19-26.
  32. Papapoulos S.E. Targeting sclerostin as potential treatment of osteoporosis. Ann. Rheum. Dis. 2011;1(70):119-22.
  33. Ross R.D., Edwards L.H., Acerbo A.S., et al. Bone Matrix Quality After Sclerostin Antibody Treatment. J. Bone Miner. Res. 2014;7(29):1597-607.
  34. Willams B. Insights into the mechanism od sclerostin action in regulating bone mass accrual. J. Bone Miner. Res. 2014;1(29):24-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies